Skip to main content
Top
Published in: Diabetologia 2/2020

Open Access 01-02-2020 | Type 1 Diabetes | Article

Plasma ascorbic acid and the risk of islet autoimmunity and type 1 diabetes: the TEDDY study

Authors: Markus Mattila, Iris Erlund, Hye-Seung Lee, Sari Niinistö, Ulla Uusitalo, Carin Andrén Aronsson, Sandra Hummel, Hemang Parikh, Stephen S. Rich, William Hagopian, Jorma Toppari, Åke Lernmark, Anette G. Ziegler, Marian Rewers, Jeffrey P. Krischer, Jill M. Norris, Suvi M. Virtanen, for the TEDDY Study Group

Published in: Diabetologia | Issue 2/2020

Login to get access

Abstract

Aims/hypothesis

We studied the association of plasma ascorbic acid with the risk of developing islet autoimmunity and type 1 diabetes and examined whether SNPs in vitamin C transport genes modify these associations. Furthermore, we aimed to determine whether the SNPs themselves are associated with the risk of islet autoimmunity or type 1 diabetes.

Methods

We used a risk set sampled nested case–control design within an ongoing international multicentre observational study: The Environmental Determinants of Diabetes in the Young (TEDDY). The TEDDY study followed children with increased genetic risk from birth to endpoints of islet autoantibodies (350 cases, 974 controls) and type 1 diabetes (102 cases, 282 controls) in six clinical centres. Control participants were matched for family history of type 1 diabetes, clinical centre and sex. Plasma ascorbic acid concentration was measured at ages 6 and 12 months and then annually up to age 6 years. SNPs in vitamin C transport genes were genotyped using the ImmunoChip custom microarray. Comparisons were adjusted for HLA genotypes and for background population stratification.

Results

Childhood plasma ascorbic acid (mean ± SD 10.76 ± 3.54 mg/l in controls) was inversely associated with islet autoimmunity risk (adjusted OR 0.96 [95% CI 0.92, 0.99] per +1 mg/l), particularly islet autoimmunity, starting with insulin autoantibodies (OR 0.94 [95% CI 0.88, 0.99]), but not with type 1 diabetes risk (OR 0.93 [95% Cl 0.86, 1.02]). The SLC2A2 rs5400 SNP was associated with increased risk of type 1 diabetes (OR 1.77 [95% CI 1.12, 2.80]), independent of plasma ascorbic acid (OR 0.92 [95% CI 0.84, 1.00]).

Conclusions/interpretation

Higher plasma ascorbic acid levels may protect against islet autoimmunity in children genetically at risk for type 1 diabetes. Further studies are warranted to confirm these findings.

Data availability

The datasets generated and analysed during the current study will be made available in the NIDDK Central Repository at https://​www.​niddkrepository.​org/​studies/​teddy.
Appendix
Available only for authorised users
Literature
10.
go back to reference Dehghan M, Akhtar-Danesh N, McMillan CR, Thabane L (2007) Is plasma vitamin C an appropriate biomarker of vitamin C intake? A systematic review and meta-analysis. Nutr J 6:41–2891-6-41CrossRef Dehghan M, Akhtar-Danesh N, McMillan CR, Thabane L (2007) Is plasma vitamin C an appropriate biomarker of vitamin C intake? A systematic review and meta-analysis. Nutr J 6:41–2891-6-41CrossRef
14.
go back to reference Zanon-Moreno V, Ciancotti-Olivares L, Asencio J et al (2011) Association between a SLC23A2 gene variation, plasma vitamin C levels, and risk of glaucoma in a Mediterranean population. Mol Vis 17:2997–3004PubMedPubMedCentral Zanon-Moreno V, Ciancotti-Olivares L, Asencio J et al (2011) Association between a SLC23A2 gene variation, plasma vitamin C levels, and risk of glaucoma in a Mediterranean population. Mol Vis 17:2997–3004PubMedPubMedCentral
22.
go back to reference American Diabetes Association (2014) Executive summary: standards of medical care in diabetes--2014. Diabetes Care 37(Suppl 1):S5–S13 American Diabetes Association (2014) Executive summary: standards of medical care in diabetes--2014. Diabetes Care 37(Suppl 1):S5–S13
Metadata
Title
Plasma ascorbic acid and the risk of islet autoimmunity and type 1 diabetes: the TEDDY study
Authors
Markus Mattila
Iris Erlund
Hye-Seung Lee
Sari Niinistö
Ulla Uusitalo
Carin Andrén Aronsson
Sandra Hummel
Hemang Parikh
Stephen S. Rich
William Hagopian
Jorma Toppari
Åke Lernmark
Anette G. Ziegler
Marian Rewers
Jeffrey P. Krischer
Jill M. Norris
Suvi M. Virtanen
for the TEDDY Study Group
Publication date
01-02-2020
Publisher
Springer Berlin Heidelberg
Keyword
Type 1 Diabetes
Published in
Diabetologia / Issue 2/2020
Print ISSN: 0012-186X
Electronic ISSN: 1432-0428
DOI
https://doi.org/10.1007/s00125-019-05028-z

Other articles of this Issue 2/2020

Diabetologia 2/2020 Go to the issue

Up Front

Up front

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.